NDZ: Nordion Inc. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, June 5, 6:02 PM Nordion (NDZ) posts a mixed FQ2, missing on a per share basis but beating on revenue. Total sales rose by 12% Y/Y, but net profit fell 77% as the medical-technology company posted significantly higher selling and administrative expenses. Targeted-therapies revenue was up 6.1%, while sterilization-technologies sales jumped 36%. Sales in the medical-isotopes segment however, were roughly flat. Total costs and expenses grew 17%, as SG&A costs rose 58%. Comment! [Healthcare, Earnings, Global & FX]
Thursday, May 23, 11:38 AM Nordion (NDZ +9%) ramps higher this morning after the company says it will divest its Target Therapies business to BTG for around $200M. That means, after fees, NDZ should rake-in nearly $185M on the closing. The sale its part of the company's larger strategic reorganization, and it's hefty price tag for a business whose sole product is its targeted liver cancer therapy, TheraSphere. Comment! [Healthcare, Global & FX]
Thursday, May 16, 10:16 AM Navidea Biopharmaceuticals (NAVB) says it's entered into an agreement with Nordion (NDZ -1%) to produce and supply its (123) labeled I-drug NAV5001 for late-phase clinical trials. NDZ will manufacture and supply of NAV5001 clinical trial material by radiolabeling NAVB's precursor drug product with Iodine-123 to form (123)I NAV5001, and then manage the logistics and shipping arrangements to third-party clinical trial sites. The agreement could be a precursor to a commercial supply arrangement in the future. Comment! [Healthcare, Global & FX]
Friday, March 22, 4:20 PM Dr. Reddy's Laboratories (RDY -1.1%) announces that it's settled claims against Nordion (NDZ +0.1%) by accepting a cash payment of $22.5M. The case was brought by RDY in April 2009 seeking damages caused by a purported breach by NDZ of its Laboratory Services Agreement with the company. 1 Comment [Global & FX, Healthcare]
Thursday, March 7, 2:21 PM Health science firm Nordion (NDZ +0.6%) ticks higher today on an upgrade at RBC Capital to Sector Perform on the back of its better than expected FQ1 earnings report yesterday, with a price target of $8 a share. The company also announced it had initiated a review of strategic alternatives with a view to enhancing shareholder value and creating new opportunities. Read more on earnings here: Earnings Call Transcript. 1 Comment [Healthcare, Earnings]
Tuesday, March 5, 5:03 PM Nordion (NDZ): FQ1 EPS of $0.07 beats by $0.04. Revenue of $53.7M (+1% Y/Y) beats by $3.7M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, March 4, 5:39 PM After-hours top gainers, as of 5:15 p.m.: ASNA +13%. SNTS +8%. CPWR +4%. NDZ +3%. MTG +3%.
After-hours top losers: IPXL -20%. JCP -6%. GMXR -6%. TVL -3%. NSU -3%. Comment! [On the Move]
Monday, January 28, 7:03 AM Nordion (NDZ): Q4 EPS of $0.34 beats by $0.08. Revenue of $74.7M (+1% Y/Y) beats by $2M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, December 12, 2012, 6:36 PM Nordion (NDZ) postpones the release of its Q4 and FY12 financial results and conference call scheduled for December 18 and 19, respectively, saying it's initiated discussions to amend the terms of the company’s credit facility. The discussions are related to the potential impact of ongoing litigation and the treatment of certain non-cash items. Shares -5.4% AH. Comment! [On the Move, Earnings]
Thursday, September 13, 2012, 10:47 AM Nordion (NDZ +1.8%) shakes up its management structure as the medical-technology company says it will realign its operations into two distinct business units with separate corporate structures: Targeted Therapies and Specialty Isotopes. The Company also appoints Jeff Brown, CEO and founding member of Brown Equity Partners, to its Board of Directors. Comment! [Healthcare, On the Move]
Monday, September 10, 2012, 12:44 PM Shares of Nordion (NDZ -35%) melt down after the company announced plans to suspend its quarterly dividend in response to an arbitration loss relating to claims against Atomic Energy of Canada for the cancelled construction of its MAPLE facilities. The facilities were the nuclear reactors and processing facility that were being constructed by AECL to serve as the source of NDZs long-term medical isotope supply. Comment! [Healthcare, Global & FX, On the Move]
Thursday, September 6, 2012, 12:43 PM Canadian medical-technology company Nordion (NDZ +0.8%) gains after its FQ3 swung to a profit on fewer one-time expenses and higher sales. The quarter marks a reversal as sales have slipped in recent quarters, due in part to supply interruptions and the temporary shutdown of a reactor. In its targeted-therapies segment, revenue grew 15%, while gross margins widened to 54.7% from 52.7%. Comment! [Healthcare, Earnings]
Wednesday, June 6, 2012, 12:44 PM Nordion (NDZ -7.2%) slides after its FQ2 missed Street expectations across the board. Revenue slipped across all of the medical-science company's main business segments, as special items weighed on Y/Y results. Comment! [Earnings, Healthcare, On the Move]
Thursday, January 19, 2012, 8:20 AM Nordion (NDZ) says it's entered a 6-year agreement to supply cobalt-60 to Synergy Health in locations across the world. The fast-growing market for Cobalt-60 products has grown to 40% of the sterilization of the world's single-use medical devices and supplies. Comment! [Healthcare]

NDZ Nordion Inc.

NDZ

Nordion Inc.